Shu-Qun Cheng (Shuqun Cheng)

Publication Activity (10 Years)

Years Active: 2022-2023
Publications (10 Years): 15

Top Topics

Metastatic Colorectal Cancer

Top Venues

Journal of oncology

Future oncology (London, England)

Cancer medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Kang Wang, Hongfei Zhu, Hongming Yu, Yuqiang Cheng, Yan-Jun Xiang, Zhangjun Cheng, Yang Li, Tao Li, Dongxu Wang, Zhenyu Zhu, Shu-Qun Cheng
Early Experience of TACE Combined with Atezolizumab plus Bevacizumab for Patients with Intermediate-Stage Hepatocellular Carcinoma beyond Up-to-Seven Criteria: A Multicenter, Single-Arm Study. Journal of oncology 2023 (2023)
Kang Wang, Hongfei Zhu, Hongming Yu, Yuqiang Cheng, Yan-Jun Xiang, Zhangjun Cheng, Yang Li, Tao Li, Dongxu Wang, Zhenyu Zhu, Shu-Qun Cheng
Early Experience of TACE Combined with Atezolizumab plus Bevacizumab for Patients with Intermediate-Stage Hepatocellular Carcinoma beyond Up-to-Seven Criteria: A Multicenter, Single-Arm Study. Journal of oncology 2023 (2023)
Zong-Han Liu, Zong-Tao Chai, Jin-Kai Feng, Yu-Chao Hou, Xiu-Ping Zhang, Zhen-Hua Chen, Yan-Jun Xiang, Wei-Xing Guo, Jie Shi, Shu-Qun Cheng
A reasonable identification of the early recurrence time based on microvascular invasion for hepatocellular carcinoma after R0 resection: A multicenter retrospective study. Cancer medicine (2023)
Nian Zhou, Feifei Mao, Shu-Qun Cheng
Mechanism Research and Application for Ginsenosides in the Treatment of Hepatocellular Carcinoma. BioMed research international 2023 (2023)
Kang Wang, Hongfei Zhu, Hongming Yu, Yuqiang Cheng, Yan-Jun Xiang, Zhangjun Cheng, Yang Li, Tao Li, Dongxu Wang, Zhenyu Zhu, Shu-Qun Cheng
Early Experience of TACE Combined with Atezolizumab plus Bevacizumab for Patients with Intermediate-Stage Hepatocellular Carcinoma beyond Up-to-Seven Criteria: A Multicenter, Single-Arm Study. Journal of oncology 2023 (2023)
Kang Wang, Hongfei Zhu, Hongming Yu, Yuqiang Cheng, Yan-Jun Xiang, Zhangjun Cheng, Yang Li, Tao Li, Dongxu Wang, Zhenyu Zhu, Shu-Qun Cheng
Early Experience of TACE Combined with Atezolizumab plus Bevacizumab for Patients with Intermediate-Stage Hepatocellular Carcinoma beyond Up-to-Seven Criteria: A Multicenter, Single-Arm Study. Journal of oncology 2023 (2023)
Wei-Jun Wang, Zong-Han Liu, Kang Wang, Hong-Ming Yu, Yu-Qiang Cheng, Yan-Jun Xiang, Jin-Kai Feng, Li-Ping Zhou, Hong-Kun Zhou, Wei-Wei Pan, Wei-Xing Guo, Jie Shi, Shu-Qun Cheng
Efficacy and safety of TACE combined with lenvatinib and PD-1 inhibitors for unresectable recurrent HCC: A multicenter, retrospective study. Cancer medicine (2023)
Kang Wang, Hong-Ming Yu, Yan-Jun Xiang, Yu-Qiang Cheng, Qian-Zhi Ni, Wei-Xing Guo, Jie Shi, Shuang Feng, Jian Zhai, Shu-Qun Cheng
Gemcitabine and cisplatin or oxaliplatin chemotherapy combined with atezolizumab plus bevacizumab for advanced biliary tract cancers: a single-arm trial. Future oncology (London, England) (2023)
Yan-Jun Xiang, Kang Wang, Hong-Ming Yu, Miao-Miao Wang, Le-Qun Li, Hui-Chuan Sun, Tian-Fu Wen, Yu-Qing Zhang, Yun-Feng Shan, Li-Ping Zhou, Shu-Qun Cheng
Hazard rate for postoperative recurrence in patients with hepatocellular carcinoma at Barcelona Clinic Liver Cancer stage 0 or A1: A multicenter observational study. Hepatology research : the official journal of the Japan Society of Hepatology 52 (11) (2022)
Kang Wang, Hong-Ming Yu, Yan-Jun Xiang, Yu-Qiang Cheng, Qian-Zhi Ni, Wei-Xing Guo, Jie Shi, Shuang Feng, Jian Zhai, Shu-Qun Cheng
Efficacy and safety of radiotherapy combined with atezolizumab plus bevacizumab in treating hepatocellular carcinoma with portal vein tumour thrombus: a study protocol. BMJ open 12 (12) (2022)
Kang Wang, Hong-Ming Yu, Yan-Jun Xiang, Yu-Qiang Cheng, Qian-Zhi Ni, Wei-Xing Guo, Jie Shi, Shuang Feng, Jian Zhai, Shu-Qun Cheng
Efficacy and safety of radiotherapy combined with atezolizumab plus bevacizumab in treating hepatocellular carcinoma with portal vein tumour thrombus: a study protocol. BMJ open 12 (12) (2022)
Kang Wang, Hong-Ming Yu, Yan-Jun Xiang, Yu-Qiang Cheng, Qian-Zhi Ni, Wei-Xing Guo, Jie Shi, Shuang Feng, Jian Zhai, Shu-Qun Cheng
Transcatheter arterial chemoembolization plus atezolizumab and bevacizumab for unresectable hepatocellular carcinoma: a single-arm, phase II trial. Future oncology (London, England) 18 (30) (2022)
Kang Wang, Hong-Ming Yu, Yan-Jun Xiang, Yu-Qiang Cheng, Qian-Zhi Ni, Wei-Xing Guo, Jie Shi, Shuang Feng, Jian Zhai, Shu-Qun Cheng
Efficacy and safety of radiotherapy combined with atezolizumab plus bevacizumab in treating hepatocellular carcinoma with portal vein tumour thrombus: a study protocol. BMJ open 12 (12) (2022)
Kang Wang, Hong-Ming Yu, Yan-Jun Xiang, Yu-Qiang Cheng, Qian-Zhi Ni, Wei-Xing Guo, Jie Shi, Shuang Feng, Jian Zhai, Shu-Qun Cheng
Efficacy and safety of radiotherapy combined with atezolizumab plus bevacizumab in treating hepatocellular carcinoma with portal vein tumour thrombus: a study protocol. BMJ open 12 (12) (2022)
Kang Wang, Hong-Ming Yu, Yan-Jun Xiang, Yu-Qiang Cheng, Qian-Zhi Ni, Wei-Xing Guo, Jie Shi, Shuang Feng, Jian Zhai, Shu-Qun Cheng
Efficacy and safety of radiotherapy combined with atezolizumab plus bevacizumab in treating hepatocellular carcinoma with portal vein tumour thrombus: a study protocol. BMJ open 12 (12) (2022)